The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Pharmacol Res. 2018 Sep;135:212-229. doi: 10.1016/j.phrs.2018.07.012. Epub 2018 Aug 11.
Traditional Chinese medicine (TCM) has served the Chinese people since antiquity, and is playing an important role in today's healthcare. However, there has been controversy in the use of these traditional herbs due to unclear components and absence of scientific proof. As China plans to modernize traditional medicine, successful attempts to better understand the molecular mechanisms of TCM have been made by focusing on isolating active ingredients from these remedies. In this review, we critically examined the current evidence on atheroprotective effects of bioactive compounds from TCM using in vitro or in vivo models in the past two decades. A total of 47 active compounds were included in our review, which were introduced in the order of chemical structures, source, model, efficacy and mechanism. Notablely, this review highlighted the cellular and molecular mechanisms of these active compounds in prevention and treatment of atherosclerosis. Two compounds were also involved in double-blind, randomized, placebo-controlled clinical trials (RCTs). Besides, we introduced the legislations of the People's Republic of China ensuring quality and safety of products used in TCM. In summary, studies on bioactive compounds from TCM will provide a new approach for better management of atherosclerosis.
中医药在中国有着悠久的历史,在当今的医疗保健中发挥着重要作用。然而,由于这些传统草药的成分不明确,缺乏科学证据,因此在使用这些草药时存在争议。随着中国计划使传统医学现代化,通过专注于从这些药物中分离活性成分,成功地尝试更好地了解中医药的分子机制。在这篇综述中,我们使用过去二十年中的体外或体内模型,批判性地检查了来自中医药的生物活性化合物对动脉粥样硬化的保护作用的现有证据。我们的综述共包括 47 种活性化合物,按化学结构、来源、模型、功效和机制的顺序进行介绍。值得注意的是,本综述强调了这些活性化合物在预防和治疗动脉粥样硬化中的细胞和分子机制。有两种化合物还参与了双盲、随机、安慰剂对照临床试验(RCT)。此外,我们还介绍了确保中医药产品质量和安全的《中华人民共和国法律法规》。总之,对中医药生物活性化合物的研究将为更好地管理动脉粥样硬化提供新的方法。